Primary tumor characteristics and survival in stage IV melanoma: A National Cancer Database analysis
Journal of the American Academy of Dermatology · 2026-11
DOI: 10.1016/j.jaad.2026.11.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-11. Verfasst von Moshe Schneiderman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Section, Veterans Affairs Boston Healthcare System, Jamaica Plain, MA; Department of Dermatology, Brigham and Women's Hospital, Boston, M…. Gefördert von: US Department of Veterans Affairs.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dermatology Section, Veterans Affairs Boston Healthcare System, Jamaica Plain, MA; Department of Dermatology, Brigham and Women's Hospital, Boston, MA; SUNY Downstate Health Sciences University, Brooklyn NY. Electronic…
- Harvard Medical School, Boston, Massachusetts.
- Dermatology Section, Veterans Affairs Boston Healthcare System, Jamaica Plain, MA; Department of Dermatology, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, Massachusetts.
Förderung
- US Department of Veterans Affairs
Zitieren
APA
Schneiderman, M., Behbahani, S., & Hartman, R. I. (2026). Primary tumor characteristics and survival in stage IV melanoma: A National Cancer Database analysis. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.11.035
Vancouver
Schneiderman M, Behbahani S, Hartman RI. Primary tumor characteristics and survival in stage IV melanoma: A National Cancer Database analysis. Journal of the American Academy of Dermatology. 2026. doi:10.1016/j.jaad.2026.11.035
BibTeX
@article{Schneiderman2026,
author = {Schneiderman, Moshe and Behbahani, Sara and Hartman, Rebecca I},
title = {Primary tumor characteristics and survival in stage IV melanoma: A National Cancer Database analysis},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
doi = {10.1016/j.jaad.2026.11.035}
}
EUVIMED